阅读说明：本技术 Mlkl抑制剂 (MLKL inhibitors ) 是由 张志远 王晓东 黄少强 闫博 刘磊 王华翌 姚郑林 韩建广 黄智� 曹伟业 于 2018-02-27 设计创作，主要内容包括：抑制细胞坏死性凋亡和/或人MLKL的嘌呤衍生物、其药物组合物,和使用有效量的化合物或组合物治疗MLKL介导的障碍的方法。所述MLKL介导的障碍为病理学相关的坏死性凋亡,包括缺血再灌注损伤、神经变性和炎性疾病,如急性胰腺炎、多发性硬化、炎性肠病和过敏性结肠炎。(Purine derivatives that inhibit necroptosis in cells and/or human MLKL, pharmaceutical compositions thereof, and methods of treating MLKL-mediated disorders using an effective amount of the compounds or compositions. The MLKL-mediated disorder is pathologically-associated necrotic apoptosis, including ischemia reperfusion injury, neurodegeneration, and inflammatory diseases, such as acute pancreatitis, multiple sclerosis, inflammatory bowel disease, and allergic colitis.)